CTOs on the Move

EraGen Biosciences

www.eragen.com

 
EraGen Biosciences, Inc. is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.eragen.com
  • 918 Deming Way
    Madison, WI USA 53717
  • Phone: 608.662.9000

Executives

Name Title Contact Details

Similar Companies

Tactile Systems Technology Inc.

Tactile Systems Technology Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Minneapolis, MN. To find more information about Tactile Systems Technology Inc., please visit www.tactilesystems.com

DOWNTOWN BRONX MEDICAL ASSOCIATES

DOWNTOWN BRONX MEDICAL ASSOCIATES is a Bronx, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Harvest Technologies Corporation

Harvest Technologies Corporation is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Plymouth, MA. To find more information about Harvest Technologies Corporation, please visit www.harvesttech.com

DermaSensor Inc.

Pioneering skin cancer tools for you and your family. DermaSensor is designing an affordable handheld sensor device that will let you scan your skin for irregular lesions in seconds.

ContraVir Pharmaceuticals, Inc

ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.